Meklozin
Meklozin
Klass : 2
Visa all info
Skriv ut
Kontakta oss
Asker C, Norstedt Wikner B, Källén B. Use of antiemetic drugs during pregnancy in Sweden. Eur J Clin Pharmacol 2005;61:899-906.
Källén B, Mottet I. Delivery outcome after the use of meclozine in early pregnancy. Eur J Epidemiol 2003;18:665-9.
Gilboa SM, Ailes EC, Rai RP, Anderson JA, Honein MA. Antihistamines and birth defects: a systematic review of the literature. Expert Opin Drug Saf. 2014;13(12):1667-98.
Etwel F, Faught LH, Rieder MJ, Koren G. The Risk of Adverse Pregnancy Outcome After First Trimester Exposure to H1 Antihistamines: A Systematic Review and Meta-Analysis. Drug Saf. 2017;40(2):121-132.
Källen B. Use of antihistamine drugs in early pregnancy and delivery outcome. J Maternal-Fetal Neonatal Med 2002;11:146-52.
Mazzotta P, Magee LA. A risk-benefit assessment of pharmacological and nonpharmacological treatments for nausea and vomiting of pregnancy. Drugs 2000;59:781-800.
- Asker C, Norstedt Wikner B, Källén B. Use of antiemetic drugs during pregnancy in Sweden. Eur J Clin Pharmacol 2005;61:899-906.
- Källén B, Mottet I. Delivery outcome after the use of meclozine in early pregnancy. Eur J Epidemiol 2003;18:665-9.
- Gilboa SM, Ailes EC, Rai RP, Anderson JA, Honein MA. Antihistamines and birth defects: a systematic review of the literature. Expert Opin Drug Saf. 2014;13(12):1667-98.
- Etwel F, Faught LH, Rieder MJ, Koren G. The Risk of Adverse Pregnancy Outcome After First Trimester Exposure to H1 Antihistamines: A Systematic Review and Meta-Analysis. Drug Saf. 2017;40(2):121-132.
- Källen B. Use of antihistamine drugs in early pregnancy and delivery outcome. J Maternal-Fetal Neonatal Med 2002;11:146-52.
- Mazzotta P, Magee LA. A risk-benefit assessment of pharmacological and nonpharmacological treatments for nausea and vomiting of pregnancy. Drugs 2000;59:781-800.